171 related articles for article (PubMed ID: 38175232)
21. Value of immunohistochemistry in crushed areas of pulmonary neuroendocrine carcinoma.
Kuçuk H; Laville D; Dal-Col P; Yvorel V; Sulaiman A; Bayle-Bleuez S; Cosmo P; Vergnon JM; Tiffet O; Desage AL; Forest F
Exp Mol Pathol; 2022 Oct; 128():104836. PubMed ID: 36206956
[TBL] [Abstract][Full Text] [Related]
22. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
González I; Lu HC; Sninsky J; Yang C; Bishnupuri K; Dieckgraefe B; Cao D; Chatterjee D
Histopathology; 2019 Oct; 75(4):568-577. PubMed ID: 31077609
[TBL] [Abstract][Full Text] [Related]
23. Breast Carcinoma With Unrecognized Neuroendocrine Differentiation Metastasizing to the Pancreas: A Potential Diagnostic Pitfall.
Christensen L; Mortensen MB; Detlefsen S
Int J Surg Pathol; 2016 Aug; 24(5):463-7. PubMed ID: 26912472
[TBL] [Abstract][Full Text] [Related]
24. Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast.
Seijnhaeve E; Galant C; Van Bockstal MR
Int J Surg Pathol; 2021 Aug; 29(5):496-502. PubMed ID: 33426999
[TBL] [Abstract][Full Text] [Related]
25. Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix.
Kuji S; Endo A; Kubota M; Uekawa A; Kawakami F; Mikami Y; Koike J; Suzuki N
J Gynecol Oncol; 2023 Jan; 34(1):e1. PubMed ID: 36245222
[TBL] [Abstract][Full Text] [Related]
26. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56.
Chen JF; Yang C; Sun Y; Cao D
Pathol Res Pract; 2020 Jun; 216(6):152993. PubMed ID: 32381384
[TBL] [Abstract][Full Text] [Related]
27. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections.
Mukhopadhyay S; Dermawan JK; Lanigan CP; Farver CF
Mod Pathol; 2019 Jan; 32(1):100-109. PubMed ID: 30154579
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
29. High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma.
Tanaka M; Shinozaki-Ushiku A; Kunita A; Yasunaga Y; Akamatsu N; Hasegawa K; Ushiku T
Pathol Int; 2022 Aug; 72(8):411-418. PubMed ID: 35698921
[TBL] [Abstract][Full Text] [Related]
30. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
[TBL] [Abstract][Full Text] [Related]
32. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
33. Top 10 Histological Mimics of Neuroendocrine Carcinoma You Should Not Miss in the Head and Neck.
Juhlin CC; Bal M
Head Neck Pathol; 2023 Mar; 17(1):66-84. PubMed ID: 36941503
[TBL] [Abstract][Full Text] [Related]
34. Metastatic Neuroendocrine Neoplasms to the Pancreas: Two Unusual Cases and a Review of the Literature.
DelBaugh RM; Kerr DA; Dominguez-Konicki L; Beard JA; Gordon SR; Adler JM; Liu X
Int J Surg Pathol; 2024 May; 32(3):523-532. PubMed ID: 37461216
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?
Bellizzi AM
Hum Pathol; 2020 Feb; 96():8-33. PubMed ID: 31857137
[TBL] [Abstract][Full Text] [Related]
36. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
[TBL] [Abstract][Full Text] [Related]
37. CytoLyt fixation impedes insulinoma-associated protein 1 (INSM1) immunoreactivity compared to formalin fixation.
Garlin-Politis M; Upadhyay Baskota S; Picon S; Collins N; Virk RK; Cimic A; Yousefi E; Gonzalez A
J Am Soc Cytopathol; 2024; 13(3):213-218. PubMed ID: 38575468
[TBL] [Abstract][Full Text] [Related]
38. Syntaxin-1 and Insulinoma-Associated Protein 1 Expression in Breast Neoplasms with Neuroendocrine Features.
Turkevi-Nagy S; Báthori Á; Böcz J; Krenács L; Cserni G; Kővári B
Pathol Oncol Res; 2021; 27():1610039. PubMed ID: 34764822
[No Abstract] [Full Text] [Related]
39. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.
Leblebici C; Yeni B; Savli TC; Aydın Ö; Güneş P; Cinel L; Şimşek BÇ; Yıldız P; Tuncel D; Kayahan S
Ann Diagn Pathol; 2019 Jun; 40():53-58. PubMed ID: 31031215
[TBL] [Abstract][Full Text] [Related]
40. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
